Resource impact statement
No significant resource impact is anticipated
We do not expect this guidance to have a significant impact on resources; that is, it will be less than £5 million per year in England (or £9,000 per 100,000 population).
This is because the technology is a further treatment option and is available at a similar price.
Risankizumab has a discount that is commercial in confidence. For enquiries about the patient access scheme please contact pricing@abbvie.com.
A resource impact template is provided for completion at a local level. This is because there are now several treatment options (biological and non-biological therapies) that are recommended by NICE for plaque psoriasis.
Organisations should complete both current and future uptake based on local practice.
This technology is commissioned by clinical commissioning groups. Providers are NHS hospital trusts.
This page was last updated: